Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

OptimizeRx Corporation - Common Stock (NQ: OPRX )

7.890 +0.210 (+2.73%)
Streaming Delayed Price Updated: 11:25 AM EDT, Sep 19, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about OptimizeRx Corporation - Common Stock

< Previous 1 2 Next >
OptimizeRx Reports First Quarter 2023 Financial Results
From OptimizeRx Corporation
Via GlobeNewswire
Surveyed Physicians Spell Out Preferences for Data-driven, Omnichannel Content That Delivers Clinical Relevance
Physicians report that they are encountering brand information across multiple digital and in-person channels, yet still lack key information on patient eligibility, affordability, and access 
From OptimizeRx Corporation
Via GlobeNewswire
OptimizeRx Sets First Quarter 2023 Conference Call for May 10, 2023at 4:30 p.m. ET
From OptimizeRx Corporation
Via GlobeNewswire
OptimizeRx Releases 2023 Environmental, Social and Governance (ESG) Report
From OptimizeRx Corporation
Via GlobeNewswire
Financial Times Ranks OptimizeRx Amongst The Americas’ Fastest Growing Companies for the Fourth Consecutive Year
– AI driven RWD deals grow from 6 completed in 2022 to several dozen in pipeline today, representing the rapid adoption of OptimizeRx’s health technology enablement platform services 
From OptimizeRx Corporation
Via GlobeNewswire
OptimizeRx Authorizes $15 Million Share Repurchase Program
From OptimizeRx Corporation
Via GlobeNewswire
OptimizeRx Announces Multi-Year Agreement with Top Hub Services Provider to Accelerate Access for Patients
Deal will enable high-growth patient services company to streamline and enhance its services with OptimizeRx’s technology solutions 
From OptimizeRx Corporation
Via GlobeNewswire
OptimizeRx Reports Fourth Quarter and Full Year 2022 Financial Results
From OptimizeRx Corporation
Via GlobeNewswire
OptimizeRx Sets Fourth Quarter & Fiscal Year 2022 Conference Call for March 8, 2023 at 4:30 p.m. ET
From OptimizeRx Corporation
Via GlobeNewswire
OptimizeRx’s Karina Castagna Named to MM+M’s 40 Under 40 List of the Medical Marketing Industry’s Brightest Young Stars
From OptimizeRx Corporation
Via GlobeNewswire
OptimizeRx CEO Issues Open Letter to Shareholders Ahead of Presentation at J.P. Morgan Healthcare Conference
From OptimizeRx Corporation
Via GlobeNewswire
OptimizeRx to Participate in Upcoming Investor Conferences
From OptimizeRx Corporation
Via GlobeNewswire
OptimizeRx Reports Third Quarter 2022 Financial Results
From OptimizeRx Corporation
Via GlobeNewswire
OptimizeRx and Melinta Therapeutics Present Third Annual Innovate4Outcomes(R) Healthcare Design Thinking-Inspired Event
Virtual event takes place December 1, 2022 
From OptimizeRx Corporation
Via GlobeNewswire
OptimizeRx Sets Third Quarter Fiscal 2022 Conference Call for Tuesday, November 8 at 4:30 p.m. ET
From OptimizeRx Corporation
Via GlobeNewswire
OptimizeRx Announces Strong Results from its use of Previously Announced AI/RWE Solution
Analysis demonstrates effectiveness of OptimizeRx’s real-world evidence solution to identify patients suitable for a specialty therapy within a narrow timeframe 
From OptimizeRx Corporation
Via GlobeNewswire
OptimizeRx Extends Omnichannel Reach With Cooler Screens Partnership
Healthcare advertising agencies can now easily add retail pharmacies to their healthcare media buying strategies 
From OptimizeRx Corporation
Via GlobeNewswire
70 Public Companies Adopt Socialsuite's ESG Disclosure Platform
Socialsuite, an ESG & Social Impact SaaS Platform, has now been adopted by 150 organizations worldwide, including more than 70 publicly traded companies with a combined market capitalization of more... 
Via Newswire.com
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.